

General prescription criteria:		
Severe asthma treated with medium-high dose ICS, LABA and OCS or other 2 nd /3 rd controller		
Insufficient asthma control (based on exacerbations, permanent OCS-dependency, AQL)		
Specific prescription criteria		
<u>Mepolizumab</u>	<u>Benralizumab</u>	<u>Dupilumab</u>
Severe eosinophilic asthma	Severe eosinophilic asthma	Severe asthma
>/= 300 eosinophils /µl in last 12 months (outside of exacerbation)	>/= 300 eosinophils /µl in last 12 months (outside of exacerbation)	FeNO >/= 25 ppb in last 12 months and/or
>/= 150 eosinophils / µl in last 12 months (outside of exacerbation) if ongoing OCS therapy	>/= 150 eosinophils / µl in last 12 months (outside of exacerbation) if ongoing OCS therapy	>/= 150 eosinophils / µl in last 12 months
Additional prescription criteria for co-morbidities: - EGPA - HES - CRSwNP	Additional prescription criteria for co-morbidities: - none	Additional prescription criteria for co-morbidities: - Neurodermitis - CRSwNP - EoE - PN

ICS – inhaled corticosteroids, LABA – long-acting beta agonists, OCS – oral corticosteroids, AQL – asthma-related quality of life, CRSwNP - Chronic Rhinosinusitis with Polyposis, EGPA: Eosinophilic Granulomatosis with Polyangiitis, EoE – Eosinophilic Esophagitis, HES – Hypereosinophilic Syndrome, PN - Prurigo nodularis.